Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06499285 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

Name: A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions — clinical trial record (NCT06499285)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorTakeda

Started2025-05-06

View on ClinicalTrials.gov ↗

The main aim of this study is to find out how well elritercept works in lowering the need for RBC transfusions. Other aims are to learn how well elritercept works in reducing the need for RBC transfusions over longer periods of time or in adults with high transfusion needs. The study will also check on how safe elritercept is and how well it is tolerated.

Amendment history 1 change detected by DataLookout

2026-05-14

Trial sites expanded: 155 → 179 locations

Trial Details

NCT Number	NCT06499285
Lead Sponsor	Takeda
Conditions	Myelodysplastic Syndromes
Enrollment	225 participants
Start Date	2025-05-06
Primary Completion	2028-05-01 (estimated)
Study Completion	2032-05-01 (estimated)
Updated on ClinicalTrials.gov	2026-08-21